IP Library Granted Patent US 11,053,529
Granted Patent B2
US 11,053,529 · App. 16/866,187 · Granted Jul 6, 2021

Activated formylglycine-generating enzymes and methods of producing and using the same

Inventors: David Rabuka (Kensington, CA); Gregory W. deHart (El Cerrito, CA); Patrick Holder (Oakland, CA); Jeanne Baker (Redwood City, CA)
Assignee: R.P. Scherer Technologies, LLC
C12P21/005A61K47/68A61K47/6889C07K16/00C07K16/32C12N9/0051C12P21/00C07K2317/14C07K2317/40C12Y108/99
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,053,529
App. No.
16/866,187
Granted
Jul 6, 2021
Kind
B2
Abstract

The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.

Claims (27)

1. A method of producing an activated formylglycine-generating enzyme (FGE), comprising contacting a human FGE with Cu 2+ to produce an activated FGE.

2. The method according to claim 1 , wherein contacting the FGE with Cu 2+ comprises culturing a cell that comprises a nucleic acid encoding the FGE in a cell culture medium that comprises Cu 2+ , wherein the culturing is under conditions in which the FGE is expressed in the cell.

3. The method according to claim 2 , wherein the Cu 2+ is present in the cell culture medium at a concentration of from 0.1 μM to 10 mM.

4. The method according to claim 2 , wherein the Cu 2+ is present in the cell culture medium at a concentration of from 1 μM to 1 mM.

5. The method according to claim 2 , wherein the FGE is endogenous to the cell.

6. The method according to claim 2 , wherein the cell is genetically modified to express an FGE.

7. The method according to claim 2 , wherein the cell is a eukaryotic cell.

8. The method according to claim 7 , wherein the eukaryotic cell is a mammalian cell.

9. The method according to claim 8 , wherein the mammalian cell is selected from the group consisting of: a CHO cell, a HEK cell, a BHK cell, a COS cell, a Vero cell, a Hela cell, an NIH 3T3 cell, a Huh-7 cell, a PC12 cell, a RAT1 cell, a mouse L cell, an HLHepG2 cell, an NSO cell, a C127 cell, a hybridoma cell, a PerC6 cell, a CAP cell, and a Sp-2/0 cell.

10. The method according to claim 7 , wherein the eukaryotic cell is a yeast cell.

11. The method according to claim 7 , wherein the eukaryotic cell is an insect cell.

12. The method according to claim 2 , wherein the cell is a prokaryotic cell.

13. The method according to claim 2 , further comprising purifying the FGE from the cell.

14. The method according to claim 1 , wherein contacting the FGE comprises expressing the FGE in a cell-free reaction mixture comprising Cu 2 ±.

15. The method according to claim 1 , wherein the FGE is contacted with Cu 2+ in a cell-free reaction mixture.

16. The method according to claim 15 , wherein elemental oxygen is present as a terminal oxidant.

17. The method according to claim 16 , wherein the elemental oxygen is provided by oxygen, a mixture of oxygen and hydrogen sulfide, or oxygen under basic conditions.

18. The method according to claim 16 , wherein the elemental oxygen is a terminal oxidant in a reaction catalyzed by Cu 2+ .

19. The method according to claim 15 , wherein the Cu 2+ is provided by a source of Cu 2+ selected from the group consisting of: copper sulfate, copper citrate, copper tartrate, Fehling's reagent, and Benedict's reagent.

20. The method according to claim 15 , wherein the FGE is an N-terminally truncated FGE.

21. The method according to claim 1 , further comprising purifying the FGE from the Cu 2+ .

22. An activated formylglycine-generating enzyme (FGE) produced by the method according to claim 1 .

23. A cell-free composition comprising:

an activated human formylglycine-generating enzyme (FGE); and

a buffer.

24. The composition of claim 23 , further comprising a protein comprising an FGE recognition site.

25. The composition of claim 23 , wherein the FGE is an N-terminally truncated FGE.

Assignments (3)
SECURITY INTEREST Recorded Dec 19, 2024
From: CATALENT CTS (KANSAS CITY), LLC; REDWOOD BIOSCIENCE, INC.; R.P. SCHERER TECHNOLOGIES, LLC; CATALENT WELLNESS, LLC; CATALENT PHARMA SOLUTIONS, INC.; CATALENT WELLNESS NEW JERSEY, LLC; CATALENT MARYLAND, INC.; CATALENT GREENVILLE, INC.; CATALENT MICRON TECHNOLOGIES, INC.; CATALENT SAN DIEGO, INC.; CATALENT WELLNESS VIRGINIA, LLC; CATALENT USA PACKAGING, LLC; CATALENT PHARMA SOLUTIONS, LLC
To: ARES CAPITAL CORPORATION, AS COLLATERAL AGENT
Reel/Frame 069743/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2020
From: RABUKA, DAVID; DEHART, GREGORY W.; HOLDER, PATRICK; BAKER, JEANNE
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 053356/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: RABUKA, DAVID; DEHART, GREGORY W.; HOLDER, PATRICK; BAKER, JEANNE
To: R.P. SCHERER TECHNOLOGIES, LLC
Reel/Frame 053213/0036 →
Continuity (6)
Division 16414202 · May 16, 2019
Continuation 15862312 · Jan 4, 2018
Division 14975403 · Dec 18, 2015
Provisional Application 62112422 · Feb 5, 2015
Provisional Application 62134461 · Mar 17, 2015
Related Publication 20200370084A1 · Nov 26, 2020